AZD3043

Phase 1Withdrawn

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Safety

Conditions

Safety, Tolerability, Pharmacokinetics, Sedation

Trial Timeline

Mar 1, 2010 → Apr 1, 2010

NCT ID

NCT01086813

About AZD3043

AZD3043 is a phase 1 stage product being developed by AstraZeneca for Safety. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01086813. Target conditions include Safety, Tolerability, Pharmacokinetics.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01086813	Phase 1	Withdrawn	Mar 1, 2010	Apr 1, 2010	Safety
NCT00984880	Phase 1	Completed	Sep 1, 2009	Dec 1, 2009	Healthy
NCT00918515	Phase 1	Completed	May 1, 2009	Aug 1, 2009	Healthy

Competing Products

20 competing products in Safety

See all competitors

Product	Company	Stage	Hype Score
LPH-5 + Placebo	Biotrial	Phase 1	25
DS-1971 + placebo	Daiichi Sankyo	Phase 1	33
ASP7962 + Placebo	Astellas Pharma	Phase 1	33
ASP2151 + Valacyclovir + Placebo	Astellas Pharma	Phase 1	33
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solution	AstraZeneca	Phase 1	33
Anifrolumab SC injection (300mg) + Anifrolumab IV infusion (300mg) + Anifrolumab SC infusion (600mg) + Anifrolumab placebo SC injection (300mg) + Anifrolumab placebo IV infusion (300mg) + Anifrolumab placebo SC infusion (600mg)	AstraZeneca	Phase 1	33
AZD7594 + Placebo to match	AstraZeneca	Phase 1	33
Anastrozole ODF + Arimidex tablet + Anastrozole ODF + Arimidex tablet	AstraZeneca	Phase 1	33
AZD4721 Solution + AZD4721 Placebo + AZD4721 Suspension	AstraZeneca	Phase 1	33
AZD9977, oral suspension + Placebo, oral suspension + AZD9977, oral solution	AstraZeneca	Phase 1	33
AZD8848 + Placebo to match AZD8848	AstraZeneca	Phase 1	33
AZD9567 Monohydrat + Placebo oral suspension/ Placebo capsule + Prednisolone	AstraZeneca	Phase 1	33
AZD7503 + Placebo	AstraZeneca	Phase 1	33
Fluad + Saline	Novartis	Approved	85
TBM100	Novartis	Approved	85
VIB9600 + Placebos	Amgen	Phase 1	32
Denosumab	Amgen	Phase 3	76
Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil	Akeso	Phase 2	51
HTL0018318 + Placebo oral capsule	Nxera Pharma	Phase 1	32
Sildenafil + Placebo + Vardenafil (Levitra, BAY38-9456) + Placebo	Bayer	Approved	82

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved